As part of an agreement announced two weeks ago, eye-disease-focused Acelyrin was due to be absorbed into immune-mediated ...

Acelyrin earlier this month agreed to an all-stock merger with fellow immune player Alumis, with their combined cash tiding ...

On February 6, 2025, ACELYRIN announced an agreement to merge with Alumis Inc. (Nasdaq: ALMS) in an all-stock transaction. The transaction is expected to close in the second quarter of 2025, subject ...

The drama introduces a potential choice for Acelyrin shareholders: cash now in a deal with Concentra or a potentially bigger return from the all-stock merger with Alumis. Two weeks after Alumis ...

Shares of Acelyrin climbed after the company said it has received an unsolicited indication of interest from Concentra Biosciences for an acquisition at $3 a share. The stock was up 14% at $2.48 in ...

Acelyrin (NASDAQ:SLRN) received an unsolicited acquisition offer from Concentra Biosciences, controlled by Tang Capital Partners. The proposal includes a cash payment of $3.00 per share, along with a ...

Agoura Hills-based biotech firm Acelyrin Inc. agreed to merge with San Francisco-based Alumis Inc. in a deal valued at $320 ...

The FDA determined that Novo Nordisk’s obesity and diabetes drugs are no longer in short supply. Elsewhere, Concentra made a ...

LOS ANGELES, Feb. 20, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative ...

Acelyrin (SLRN) “confirmed receipt of an unsolicited indication of interest from Concentra Biosciences, LLC, of which Tang Capital Partners, LP ...